NCT05839444已完成不适用
A Pilot Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Tolerability of BioPB-01 in Healthy Adults
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 4
- 主要终点
- To evaluate the safety of 21 days of BioPB-01 administration on
研究概览
简要总结
The present study is a randomized, placebo-controlled, parallel-group, double-blind clinical study. Seventy-eight individuals will be screened, and considering a screening failure rate of 20%, approximately 64 participants will be randomized in a ratio of 1:1 to receive either BioPB-01 or Placebo
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Stratified block randomization, Sequentially numbered, sealed, opaque envelopes
入排标准
- 年龄范围
- 25 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants who are 25 to 55 years of age (inclusive) at the time ofsigning the informed consent form.
- •Participants having good general health (no active or uncontrolled diseases, infections, or conditions).
- •BMI within the range of 24.9 to 34.9 kg/m2 (inclusive).
- •Random blood glucose level <140 mg/dL.
- •Concurrent metformin use is acceptable for indications other than diabetes. (However, the subject and investigator must not change metformin dosing during the three weeks of the study).
- •Non-pregnant and non-lactating females of childbearing potential who agree to use adequate contraception/sexual abstinence throughout the study period.
- •Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.
- •Individuals with access to a digital device to fill out the questionnaires.
排除标准
- •Participant has a history of uncontrolled hypertension (i.e., ≥150 mmHg systolic and/or ≥110 mmHg diastolic).
- •Participant with history of post-prandial hypoglycemia (occurring 2-5 hours after food intake) of unknown cause.
- •Abnormal thyroid-stimulating hormone (TSH) levels (<0.4 or > 4.2 μIU/ml).
- •Known case of Type 1 or 2 diabetes.
- •Participant has a history of heart disease and/or cardiovascular disease, kidney disease (dialysis or renal failure), and/or hepatic impairment or disease.
- •Participant has a history of previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the year prior to screening, immune disorder (i.e., HIV/AIDS), or a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to the screening visit.
- •Received a vaccine for COVID-19 or any other vaccination in the 2 weeks prior to screening or planned during the study period, currentCOVID-19 infections, or currently have the post COVID-19 condition as defined by the World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis).
- •Have a known intolerance, sensitivity, or allergy to any of the study products, their ingredients, or any excipients used in the formulation.
- •Individuals who have a known history of diverticulitis.
- •Have a known intolerance, sensitivity, or allergy to milk or soy.
- •Any condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of the study data.
- •Currently taking dietary supplements other than vitamins and minerals.
- •Taking any other prescription medication at the time of randomization that is known to impact blood sugar and or blood sugar metabolism, as per the Principal Investigator's (PI) discretion.
- •History of smoking, alcohol (heavy drinking as defined by NIAAA [National Institute on Alcohol Abuse and Alcoholism], USA), or substance abuse in the 12 months prior to screening.
- •Receipt or use of an investigational product in another research study within 30 days prior to baseline/Visit 2.
结局指标
主要结局
To evaluate the safety of 21 days of BioPB-01 administration on
时间窗: Throughout the study (an average of 21 days)
The number and percentage of participants having adverse product reaction (as per CTCAE V5.0)
次要结局
- To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing the metabolic health(Day 21)
- To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing Fecal short chain fatty acids (SCFA)(Day 21)
- To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing(Day 21)
研究者
研究点 (4)
Loading locations...
相似试验
终止
4 期
Dextromethorphan Pediatric Acute Cough StudyCoughNCT02651116Pfizer131
已完成
2 期
Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel DiseaseUlcerative Colitis Chronic MildUlcerative Colitis Chronic ModerateCrohn ColitisNCT05194007Mohammed Bin Rashid University of Medicine and Health Sciences13
已完成
不适用
A Study to Assess the Effect of the Bio-K+ Probiotic Capsules (VL-BK-02) in Adults With Functional ConstipationFunctional ConstipationNCT06730594Vedic Lifesciences Pvt. Ltd.168
终止
2 期
Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19COVID-19NCT04474483State University of New York at Buffalo8
撤回
4 期
Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic ManiaBipolar I DisorderNCT01495156Northwell Health